Spikevax LP.8.1 COVID-19 mRNA vaccine
Spikevax LP.8.1 is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.
In agreement with Panamerican Health Organization (PAHO), Moderna will supply doses to member states for use based on the Federal Commission for Protection against Health Risks (COFEPRIS) as a reference regulatory authority.
Spikevax LP.8.1 COVID-19 mRNA vaccine – Pre filled Syringe
Spikevax LP.8.1 Prefilled Syringe is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
In agreement with Panamerican Health Organization (PAHO), Moderna will supply doses to member states for use based on the U.S Food and Drug Administration (FDA) as a reference regulatory authority.